A phase two clinical trial of the personalized peptide vaccine for standard therapy-resistant pediatric cancer patients
- Conditions
- The pediatric patients who are resistant for standard therapy.
- Registration Number
- JPRN-UMIN000023422
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
The following patients must be excluded : 1) Patients with severe symptoms (active and severe infections, circulatory disease, respiratory disease, kidney disease,immunodeficiency, disturbance of coagulation). 2) Active double cancer (synchronous double cancer and meta-chronous double cancer within 3 disease-free years),excluding carcinoma in situ (lesions equal to intra-epithelial or intra-mucosal cancer) judged to have been cured with local treatment. 3) Patients with leukemia 4) Patients with the past history of severe allergic reactions. 5) Patients who hope for pregnancy 6) Patients who do not accept contraception from the 1st vaccination until 70 days after the last vaccination. 7) Patients who are judged inappropriate for entry to this trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of immune response by measurement of peptide specific IgG before and after peptide vaccination
- Secondary Outcome Measures
Name Time Method Safety assessment (Observation of side effects) Clinical effectiveness(overall survival period)